The Influence of Pulse-synchronized Negative Pressure on the Dermal Microcirculation (PSyNeP)

The technology of the pulse-synchronous alternating pressure system has been patented and is ready for application. Since the device is a combination of commercially available products with a software controlling the duration/initiation of the negative pressure, no harm for the study participant is expected. With no adequate preclinical model of impaired microcirculation being available, and due to the non-invasive nature of the device, the rationale to test the product in a controlled setting in clinical patients is justified. The intervention takes place twice a day for two consecutive days with objective assessment of the microcirculation before and after the intervention. Thereby, the immediate effect of the intervention is to be evaluated. A fifth assessment takes place on the third day without prior intervention to assess a possible long-term effect (comparison against first measurement - base line).

The primary aim of this project is to investigate the tolerability and the comfort of pulse-synchronized negative pressure (PSNP) applied by the device manufactured by Orputec GmbH on the dermal microcirculation. Evaluation of patient comfort and tolerability will be performed by a Numerical Rating Scale (NRS).

The application of the device (PSNP) significantly influences the dermal microcirculation (measuring by LD, HS, TH).

The aims of this project is to investigate the tolerability / comfort and the effect of pulse-synchronized negative pressure (PSNP) applied by the device manufactured by Orputec GmbH on the dermal microcirculation. Objective evaluation of microcirculation with laser doppler (LD), hyperspectral imaging (HS), thermal imaging (TH).

Study Overview

• Status: Terminated
• Conditions: Diabetes; Microcirculation
• Intervention / Treatment: Device: pulse-synchronized negative pressure (PSNP) device; Other: Control - no intervention

Detailed Description

Orputec has developed a device that uses the technology of a pulse-synchronized alternating pressure system. It can be applied in the field of regenerative medicine to treat lymphedema by improving the blood- and lymphatic circulation. The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software controlling the timing of suction and drainage, and an individual suction cap for each patient.

The study is designed as an open, interventional cohort, intraindividually controlled, pilot study. A pilot sample size of 12 is chosen because the device will be tested in a controlled setting for the first time. No formal sample size calculation was performed.

The collective consists of 12 subjects, with diabetes mellitus (DM) type 2 but no apparent wounds on the lower leg. Before inclusion, subjects will be screened for current skin lesions in the region of interest (ROI), comorbidities, and their medical history concerning diabetes and skin lesions. The ROI on both lower legs will be marked, and the dermal microcirculation will be measured, non-invasively, using LD, HS, and TH. After ensuring a comfortable position, each subject will receive treatment with the PSNP device on one chosen lower leg for 120 minutes. During the treatment, a warming unit, which is also used after flap surgery to maintain an adequate ambient temperature, will be used to obtain local thermal hyperaemia, hence a prospected dilation of the vessels. The non-invasive imaging (LD, HS, TH) will be performed before and after the intervention. This treatment course will be applied twice a day (with 4h +/- 2h in between) for two consecutive days. Toleration of the treatment and wellbeing of the subjects will be assessed by a Visual Analog Scale (VAS). Finally, another series of imaging (LD, HS, TH) will be performed on the morning of the third day without a prior intervention.

Statistical analysis of numeric endpoints: All numeric endpoints will be checked for normality, e.g. by using a Shapiro-Wilk test. If a numeric endpoint deviates from normality, then data transformations (e.g. log-transformation) will be considered. Numeric endpoints will be analysed by means of a repeated measures analysis of variance (ANOVA). The level of significance will be set to 5% in all analyses. No adjustment for multiple comparisons will be performed.

Additionally, the following comparisons will be performed by using descriptive statistics (e.g. Q1, median, Q3, mean, standard deviation) and graphical methods (e.g. box plots):

• Comparison of time points (prior to intervention on day 1; after intervention on day 1; prior to control on day 1; after control on day 1 and day 3) within each treatment condition (intervention: treated leg; control: untreated leg).
• Comparison of treatment conditions (treated vs. untreated legs) for each time point.

In order to identify influencing factors for the effect of the PSNP treatment, the investigators will use graphical methods as well as regression models and mixed effects models (e.g., analysis of covariance).

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Austria
  • Styira
    • Graz, Styira, Austria, 8036
      • Division of Plastic, Aesthetic and Reconstructive Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female individuals suffering from DM type 2 and willing to participate in this study
• First diagnosis of DM type 2 at least 10 years prior to inclusion OR presence of diabetic dermopathy.
• Age: 45-99
• Written consent of the participant after being informed

Exclusion Criteria:

• Skin lesions or dermatoses in the region of interest (ROI)
• Non-ability to comprehend the nature and course of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: pulse-synchronized negative pressure (PSNP) device; One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.

Device: pulse-synchronized negative pressure (PSNP) device; The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.; Other: Control - no intervention; The other leg serves as non-treated control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale	Successful intervention with the PSNP device without harm to the patients. Change of toleration of the treatment and wellbeing of the subjects will be assessed by a Numerical Rating Scale (scale 0 - 10)	2 times on day 1 and day 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of microcirculation with laser doppler (LD)	LD is measuring the blood flow: Blood flow is then calculated in a unit called Flux based on the red cell concentration in red cell velocity. The blood flow correlates directly to the microcirculation in the skin. A higher blood flow indicates a better microcirculation.	4 times on day 1 and 2; once on day 3
Change of microcirculation with hyperspectral imaging (HS)	HS is measuring oxygenation in the blood: The oxygenation index is given in percent. The oxygenation correlates directly to the microcirculation in the skin. A higher blood oxygenation indicates a better microcirculation.	4 times on day 1 and 2; once on day 3
Change of microcirculation with thermal imaging (TH)	Objective evaluation of microcirculation with thermal imaging (TH). TH is measuring the skin temperature in Kelvin. The skin temperature correlates directly to the blood flow and the microcirculation in the skin. A higher skin temperature indicates a better microcirculation.	4 times on day 1 and 2; once on day 3

Collaborators and Investigators

• Sponsor: Orputec
• Collaborators: Medical University of Graz; Joanneum Research Forschungsgesellschaft mbH
• Investigators: Principal Investigator: Lars-Peter Kamolz, Univ.-Prof., Medical University of Graz, Graz, Styria, Austria

Study record dates

Study Major Dates

• Study Start (Actual): May 28, 2021
• Primary Completion (Actual): May 17, 2022
• Study Completion (Actual): May 17, 2022

Study Registration Dates

• First Submitted: June 17, 2021
• First Submitted That Met QC Criteria: July 5, 2021
• First Posted (Actual): July 14, 2021

Study Record Updates

• Last Update Posted (Actual): July 11, 2022
• Last Update Submitted That Met QC Criteria: July 7, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: PSyNeP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No